A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Facial Volume Deficit
Interventions
DEVICE

HAC 22L

Subcutaneous and/or Supraperiosteal injection

Trial Locations (17)

14467

Haut- und Lasercentrum Potsdam /ID# 243822, Potsdam

15831

Dermatologische Gemeinschaftspraxis Mahlow /ID# 243805, Blankenfelde-Mahlow

20146

Universitaet Hamburg /ID# 251970, Hamburg

28001

Instituto de Medicina y Dermatologia Avanzada (IMDA) /ID# 243339, Madrid

Sclinic /Id# 243340, Madrid

28006

Grupo Pedro Jaen /ID# 243347, Madrid

28009

Instituto de Dermatologia Integral (IDEI) /ID# 245764, Madrid

29016

Instituto Medico Miramar /ID# 251640, Málaga

34117

Noahklinik GmbH /ID# 244610, Kassel

40212

Privatpraxis Dr. Hilton & Partner /ID# 243798, Düsseldorf

44793

Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus /ID# 243802, Bochum

50996

Hautzentrum Koeln /ID# 244607, Cologne

61440

MediCorium Zentrum fuer Dermatologie und Aesthetik /ID# 243799, Oberursel

64283

Rosenpark Research /ID# 243804, Darmstadt

80333

Hautok and Hautok-cosmetics /ID# 243800, Munich

80539

Privatpraxis fuer Dermatologie und Aesthetik /ID# 243803, München

08021

Antiaging Group Barcelona (AGB) /ID# 245446, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY